Jounce Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2016 to Q4 2022

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Jounce Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2016 to Q4 2022.
  • Jounce Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending December 31, 2022 was $51M.
  • Jounce Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending December 31, 2022 was -$50.9M, a 44% increase year-over-year.
  • Jounce Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$50.9M, a 44% increase from 2021.
  • Jounce Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$90.9M, a 107% decline from 2020.
  • Jounce Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2020 was -$43.8M, a 177% decline from 2019.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2022 -$50.9M $51M +$81.2M Oct 1, 2022 Dec 31, 2022 10-K/A 2023-04-28
Q3 2022 -$132M -$31M -$905K -3.01% Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-10
Q2 2022 -$131M -$33.5M -$29.5M -736% Apr 1, 2022 Jun 30, 2022 10-Q 2022-11-10
Q1 2022 -$102M -$37.4M -$10.8M -40.8% Jan 1, 2022 Mar 31, 2022 10-Q 2022-11-10
Q4 2021 -$90.9M -$30.2M -$65.7M -185% Oct 1, 2021 Dec 31, 2021 10-K/A 2023-04-28
Q3 2021 -$25.2M -$30.1M -$5.19M -20.8% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$20M -$4.01M +$24M +85.7% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-10
Q1 2021 -$43.9M -$26.5M -$92K -0.35% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-10
Q4 2020 -$43.8M $35.5M +$58.1M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-02
Q3 2020 -$102M -$24.9M -$124M -125% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $21.8M -$28M -$21M -300% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-04
Q1 2020 $42.8M -$26.4M -$14.1M -114% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-04
Q4 2019 $56.8M -$22.7M -$20.6M -1011% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-25
Q3 2019 $77.5M $98.9M +$106M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-06
Q2 2019 -$29M -$6.99M -$2.32M -49.6% Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-06
Q1 2019 -$26.7M -$12.4M +$651K +5% Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-06
Q4 2018 -$27.4M -$2.04M +$7.32M +78.2% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-27
Q3 2018 -$34.7M -$7.64M -$3.55M -87% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 -$31.2M -$4.67M -$1.29M -38.3% Apr 1, 2018 Jun 30, 2018 10-Q 2019-11-07
Q1 2018 -$29.9M -$13M -$13.4M -3484% Jan 1, 2018 Mar 31, 2018 10-Q 2019-11-07
Q4 2017 -$16.4M -$9.36M -$14.8M -271% Oct 1, 2017 Dec 31, 2017 10-K 2018-03-08
Q3 2017 -$1.61M -$4.08M -$8.15M -200% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-13
Q2 2017 $6.54M -$3.38M +$8.97M +72.6% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
Q1 2017 -$2.43M $385K +$11.3M Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
Q4 2016 -$13.7M $5.47M Oct 1, 2016 Dec 31, 2016 10-K 2018-03-08
Q3 2016 $4.07M Jul 1, 2016 Sep 30, 2016 10-K 2018-03-08
Q2 2016 -$12.3M Apr 1, 2016 Jun 30, 2016 10-K 2018-03-08
Q1 2016 -$10.9M Jan 1, 2016 Mar 31, 2016 10-K 2018-03-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.